Vaccine demand was once among the more predictable areas of pharma.

National immunisation schedules, public procurement and established reimbursement channels gave manufacturers unusual visibility over volumes. Shifting US recommendations are now weakening that certainty, with consequences for uptake, revenue forecasts and manufacturing capacity.

Visiongain forecasts the global vaccine sales market to grow from US$76.40bn in 2026 to US$141.40bn by 2036, at a CAGR of 6.3%. The market is expanding, but policy is making company-level demand harder to forecast.

Access Visiongain’s free vaccine briefing – The New Vaccine Growth Model

Visiongain Top Takeaways

• Recommendation changes can move demand quickly: Shared clinical decision-making may preserve coverage, but it adds friction and makes uptake less predictable.
• Coverage is not the same as access: Billing, provider participation, pharmacy processes and local supply still determine whether patients are vaccinated.
• Procurement concentration raises earnings risk: One stockpile contract, government programme or renewal decision can materially change demand.
• Policy divergence is increasing commercial complexity: Different national frameworks require more localised evidence, market-access and supply strategies.
• Policy uncertainty is reaching manufacturing: Manufacturers and CDMOs must commit capacity before demand is clear, but cutting too deeply risks being unable to respond when orders return.

Recommendations Now Shape the Commercial Outlook

Vaccine guidance influences far more than clinical practice. It affects purchasing, provider stocking, patient awareness and how easily a product reaches eligible populations.

In the US, shared clinical decision-making does not necessarily remove insurance coverage. It replaces routine use with an individual discussion between patient and provider, adding another step before vaccination. Uptake can therefore weaken even when the product remains approved and reimbursed.

Pfizer reported first-quarter 2026 Comirnaty revenue of US$232m, down 59% year on year, as the post-pandemic COVID-19 vaccine market continued to contract.

Visiongain Insight: Policy status now belongs in vaccine demand forecasts. A product may retain approval and coverage yet generate lower and less predictable sales when it is no longer treated as routine.

Coverage Does Not Guarantee Access

Insurance coverage does not guarantee that a vaccine will be stocked, offered or administered.

Providers may be reluctant to hold inventory where demand is uncertain, wastage risk is high, or reimbursement is cumbersome. Pharmacy procedures, local supply and additional documentation can create further barriers.

Historical uptake is therefore becoming a weaker guide to future demand, increasing the risk of excess or insufficient inventory.

Procurement Can Create or Remove a Market

Beyond reimbursement and delivery, government purchasing can determine whether a vaccine market exists at all.

Advance purchase agreements, national stockpiles and preparedness programmes can create demand before a broad commercial market has developed. Guaranteed volumes can also support manufacturing investment that would otherwise be difficult to justify.

That support can disappear quickly. Delayed, reduced or cancelled orders can remove expected revenue and leave suppliers committed to volumes that no longer exist.

Pooled procurement through organisations such as Gavi, UNICEF and the Pan American Health Organization can open large markets and shape the supplier base. These opportunities are often price-sensitive and depend on donor funding, tender cycles and changing public-health priorities.

Company exposure becomes more acute where revenue depends on a small number of buyers or partners. Novavax is increasingly pursuing a licensing and collaboration model, while Emergent BioSolutions remains closely tied to government preparedness procurement.

In these businesses, one renewal, pricing decision or contract delay can materially change the earnings outlook.

Visiongain Insight: Contract concentration deserves the same scrutiny as product concentration. Category growth offers limited protection when company revenue depends on a small number of buyers, tenders or partners.

One Product, Several Policy Markets

The same vaccine can face a different commercial outlook across major markets.

The US, UK and Germany use separate recommendation processes, evidence standards and procurement models. A product supported for broad use in one country may face a narrower eligible population, a tougher economic threshold or a different purchasing route elsewhere.

Manufacturers increasingly need country-specific evidence, demand forecasts and launch plans for the same asset. These differences can affect where a product launches first, how much capacity is allocated and whether further investment in a market is justified.

National policy now shapes launch sequencing and the commercial case in each market, making forecasts based on one global adoption pattern increasingly unreliable.

Demand Volatility Reaches Manufacturing

Pandemic-era vaccine capacity was built for volumes that have not been sustained. Specialised facilities are costly to maintain and cannot always be closed, converted or restarted quickly.

Low utilisation pushes up unit costs, but removing capacity carries its own risk. An outbreak, expanded eligibility or government order can raise demand faster than production can be restored.

CDMOs face the same calculation. Capacity added for COVID-19 and RSV programmes may remain underused when customer forecasts fall, while consolidation can leave too little room to respond when demand recovers.

The issue is not simply how much capacity the industry needs, but how much readiness manufacturers are prepared to fund during periods of weaker utilisation.

Visiongain Insight: Vaccine capacity planning is now partly a policy forecast. Manufacturers must balance present utilisation against the cost and time required to restore production later.

Concentration Risk Varies Sharply by Company

Policy and demand shifts do not affect every vaccine company equally.

GSK’s breadth across vaccine categories and geographies provides room to offset weakness in individual franchises. Pfizer and Merck also benefit from much larger medicines businesses, although weaker Gardasil demand in China showed that a single product-market exposure can still weigh on vaccine performance.

Moderna has less protection from these shifts because its marketed portfolio remains centred on respiratory vaccines. Progress in oncology and other pipeline areas will not reduce that concentration unless new programmes reach the market.

The distinction is between diversification at group level and within the vaccine portfolio. A company can be broad overall while retaining meaningful exposure to one product, geography or seasonal market.

Market Outlook

Category growth will not remove company-level volatility.

National recommendations, procurement decisions and access conditions will continue to produce different adoption patterns for the same vaccine across markets.

This will place greater value on scenario-based forecasting, flexible supply agreements and evidence strategies that can be adapted by country.

Scientific performance will still determine whether products reach approval. Commercial performance will depend increasingly on how policy, reimbursement and procurement convert that approval into administered doses.

Visiongain Insight: Vaccine forecasts can no longer rely on a single adoption curve. Policy, uptake and procurement scenarios should be tested before investment and capacity decisions are made.

From Visiongain: Vaccines Intelligence Hub

Vaccine markets are being reshaped by new platforms, shifting policy, changing demand and growing pressure on manufacturing and delivery.

Visiongain’s Vaccines Intelligence Hub brings together briefings, analysis and market insight on the forces shaping the sector, from mRNA and cancer vaccines to manufacturing, next-generation delivery, procurement and commercial strategy.

Explore the Vaccines Intelligence Hub for strategic updates and related market reports.

Related reports include:

• Vaccine Sales Market Report 2026–2036
• mRNA Vaccines Market Report 2026–2036
• mRNA Cancer Vaccine Market Report 2026–2036
• Vaccine Contract Manufacturing Market Report 2026–2036

Press & Media Enquiries

For commentary, data requests or interview enquiries, please contact: press@visiongain.com